Myriad Genetics Stock

Myriad Genetics Equity

The The Equity of Myriad Genetics (MYGN) as of Aug 16, 2026 is 368.00 M USD. In the previous year, The Equity was 701.10 M USD — a change of -47.51% (lower).

Equity

368.00 MUSD

YoY

-47.51%

Last updated:

In 2026, Myriad Genetics's equity was 368.00 M USD, a -47.51% increase from the 701.10 M USD equity in the previous year.

Access this data via the Eulerpool API
Get Free API Key

Myriad Genetics Stock analysis

What does Myriad Genetics do? Myriad Genetics Inc. is a biotechnology company specializing in the research of cancer and genetic analysis technologies. The company was founded in 1991 by Mark Skolnick and has since become a global leader in personalized medicine and diagnostics. It is headquartered in Salt Lake City, Utah, USA, and employs over 2,400 employees worldwide. Myriad Genetics is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Myriad Genetics's Equity

Myriad Genetics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Myriad Genetics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Myriad Genetics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Myriad Genetics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Myriad Genetics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Myriad Genetics stock

The Equity of Myriad Genetics is 368.00 M USD in 2026.

The Equity of Myriad Genetics changed from 701.10 M USD to 368.00 M USD, representing a -47.51% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Myriad Genetics since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Myriad Genetics historically and in real time.

Access this data via the Eulerpool API
Get Free API Key

Balance Sheet — Myriad Genetics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Myriad Genetics